In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy

Annals of Surgery

Volumn 251, Issue 6, 2010, Pages 1079-1086

  Kojima, Toru ^a   Watanabe, Yuichi ^b,c   Hashimoto, Yuuri ^b,c   Kuroda, Shinji ^a   Yamasaki, Yasumoto ^a   Yano, Shuya ^a   Ouchi, Masaaki ^c   Tazawa, Hiroshi ^a   Uno, Futoshi ^a,b   Kagawa, Shunsuke ^a,b   Kyo, Satoru ^d   Mizuguchi, Hiroyuki ^e   Urata, Yasuo ^c   Tanaka, Noriaki ^a   Fujiwara, Toshiyoshi ^a,b  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c National Institute of Infectious Diseases   (Japan)

^d KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OBP 301; ONCOLYTIC ADENOVIRUS; TELOMELYSIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ALU SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; METASTASIS INHIBITION; MICROMETASTASIS; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL DESTRUCTION; VIRUS REPLICATION;

ALU ELEMENTS; ANIMALS; COLORECTAL NEOPLASMS; HT29 CELLS; HUMANS; INJECTIONS, INTRALESIONAL; LYMPH NODES; LYMPHATIC METASTASIS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; POLYMERASE CHAIN REACTION; TELOMERASE;

EID: 77953027875     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181deb69d     Document Type: Article

References (27)

1. Maehara Y, Oshiro T, Endo K, et al. Clinical significance of occult micro-metastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery. 1996;119:397-402.
2. Rivadeneira DE, Simmons RM, Christos PJ, et al. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg. 2000;191:1-6.
3. Chang GJ, Rodriguez-Bigas MA, Skibber JM, et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99:433-441.
4. Volpe CM, Koo J, Miloro SM, et al. The effect of extended lymphadenec-tomy on survival in patients with gastric adenocarcinoma. J Am Coll Surg. 1995;181:56-64.
5. Harrison LE, Karpeh MS, Brennan MF. Extended lymphadenectomy is associated with a survival benefit for node-negative gastric cancer. J Gas-trointest Surg. 1998;2:126-131.
6. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453-462.
7. Gotoda T, Sasako M, Ono H, et al. Evaluation of the necessity for gastrec-tomy with lymph node dissection for patients with submucosal invasive gastric cancer. Br J Surg. 2001;88:444-449. (Pubitemid 32238711)
8. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol. 2007;4:101-117.
9. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009;9:64-71.
10. Fujiwara T. Telomerase-specific virotherapy for human squamous cell carcinoma. Expert Opin Biol Ther. 2009;9:321-329.
11. Kawashima T, Kagawa S, Kobayashi N, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004;10:285-292.
12. Umeoka T, Kawashima T, Kagawa S, et al. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res. 2004;64:6259-6265.
13. Taki M, Kagawa S, Nishizaki M, et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (Telomelysin-RGD). Oncogene. 2005;24:3130-3140.
14. Fujiwara T, Tanaka N, Numunaitis JJ, et al. Phase I trial of intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, in patients with advanced solid cancer: evaluation of biodistribution and immune response. J Clin Oncol. 2008;26:3572.
15. Kishimoto H, Kojima T, Watanabe Y, et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med. 2006;12:1213-1219.
16. Johnson M, Huyn S, Burton J, et al. Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther. 2006;17:1262-1269.
17. Burton JB, Johnson M, Sato M, et al. Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med. 2008;14:882-888.
18. Schneider T, Osl F, Friess T, et al. Quantification of human Alu sequences by real-time PCR\an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants. Clin Exp Metastasis. 2002; 19:571-582.
19. Zijlstra A, Mellor R, Panzarella G, et al. A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time poly-merase chain reaction. Cancer Res. 2002;62:7083-7092.
20. Umetani N, Giuliano AE, Hiramatsu SH, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006;24:4270-4276.
21. Kariya Y, Kato K, Hayashizaki Y, et al. Revision of consensus sequence of human Alu repeats\a review. Gene. 1987;53:1-10.
22. Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res. 2007;67:429-432.
23. Kurihara Y, Watanabe Y, Onimatsu H, et al. Telomerase-specific virother-anostics for human head and neck cancer. Clin Cancer Res. 2009;15:2335-2343.
24. Kawabata K, Sakurai F, Koizumi N, et al. Adenovirus vector-mediated gene transfer into stem cells. Mol Pharm. 2006;3:95-103.
25. Hiyama K, Hirai Y, Kyoizumi S, et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol. 1995;155:3711-3715.
26. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008;320:226-230.
27. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15-18.